Related Experiment Videos
Targeting HER1/EGFR: a molecular approach to cancer therapy
1Division of Oncology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232-6307, USA.
Abstract:
The varying efficacy and toxicity of traditional cancer therapies has driven the development of novel target-based agents. Members of the HER (Human Epidermal Receptor) family, in particular epidermal growth factor receptor (HER1/EGFR), are attractive therapeutic targets because they are overexpressed and/or dysregulated in many solid tumors. Activation of HER1/EGFR mediated through ligand binding triggers a network of signaling processes that promote tumor cell proliferation, migration, adhesion, and angiogenesis, and decrease apoptosis. Therefore, inhibiting HER1/EGFR activity could effectively block downstream signaling events and, consequently, tumorigenesis. Various approaches are being investigated to target members of the HER family, particularly HER1/EGFR and HER2. At the forefront are monoclonal antibodies and small molecules that inhibit the receptor tyrosine kinase activity. Monoclonal antibodies have been developed that act against HER1/EGFR and HER2. Monoclonal antibodies block ligand binding and prevent ligand-induced activation. Tyrosine kinase inhibitors block receptor phosphorylation, preventing downstream signal transduction. Several HER1/EGFR-targeted agents are advanced in clinical development and attention is focused on optimizing their clinical use. While this process may prove challenging, it promises to be beneficial.
Insights
Novel targeted therapies are being developed to combat cancer due to the limitations of traditional treatments. Targeting the Human Epidermal Receptor (HER) family, especially HER1/EGFR, shows promise in blocking tumor growth by inhibiting key signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Traditional cancer therapies exhibit variable efficacy and toxicity.
- Members of the Human Epidermal Receptor (HER) family, particularly HER1/EGFR, are frequently overexpressed or dysregulated in solid tumors.
- HER1/EGFR activation drives tumor cell proliferation, migration, adhesion, angiogenesis, and inhibits apoptosis.
Purpose of the Study:
- To explore novel target-based agents for cancer therapy.
- To investigate the potential of inhibiting HER1/EGFR activity to block downstream signaling and tumorigenesis.
- To review current approaches targeting HER family members, focusing on HER1/EGFR and HER2.
Main Methods:
- Development of monoclonal antibodies targeting HER1/EGFR and HER2.
- Design of small molecules inhibiting the receptor tyrosine kinase activity of HER family members.
- Investigation of agents that block ligand binding or receptor phosphorylation.
Main Results:
- Monoclonal antibodies prevent ligand binding and receptor activation.
- Tyrosine kinase inhibitors block receptor phosphorylation and downstream signal transduction.
- Several HER1/EGFR-targeted agents have advanced into clinical development.
Conclusions:
- Inhibiting HER1/EGFR effectively blocks tumor-promoting signaling pathways.
- Targeted agents, including monoclonal antibodies and tyrosine kinase inhibitors, offer promising therapeutic strategies.
- Optimizing the clinical use of HER1/EGFR-targeted agents is a key focus, with potential for significant patient benefit.